Cellular immunity of patients with malignant glioma: Prerequisites for dendritic cell vaccination immunotherapy

Journal of Neurosurgery

Volumn 105, Issue 1, 2006, Pages 41-50

  Rapp, Marion ^a   Özcan, Zakir ^a   Steiger, Hans Jakob ^a   Wernet, Peter ^a   Sabel, Michael C ^a   Sorg, Rüdiger V ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Dendritic cell; Glioma; Immunotherapy; Tumor vaccine

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; LECTIN; LOMUSTINE; PROCARBAZINE; T6 ANTIGEN; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD AUTOTRANSFUSION; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE STATUS; IMMUNOTHERAPY; LEUKOCYTE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADULT; ANTIGENS, CD; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; GLIOMA; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTE COUNT; MALE; MIDDLE AGED;

EID: 33745565415     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2006.105.1.41     Document Type: Article

References (51)

1. Ashkenazi E, Deutsch M, Tirosh R, Weinreb A, Tsukerman A, Brodie C: A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation. Neuroimmunomodulation 4:49-56, 1997
2. Ausiello C, Maleci A, Spagnoli GC, Antonelli G, Cassone A: Cell-mediated cytotoxicity in glioma-bearing patients: differential responses of peripheral blood mononuclear cells to stimulation with interleukin-2 and microbial antigen. J Neurooncol 6:329-338, 1988
3. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al: Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811, 2000
4. Bhondeley MK, Mehra RD, Mehra NK, Mohapatra AK, Tandon PN, Roy S, et al: Imbalances in T cell subpopulations in human gliomas. J Neurosurg 68:589-593, 1988
5. Blom U, Blomgren H, Ullen H, Collins P, Von Holst H: Mitogen stimulation of blood lymphocytes from patients with primary intracranial tumors. Correlation to histological tumor type. Anticancer Res 5:343-348, 1985
6. Braun DP, Penn RD, Flannery AM, Harris JE: Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery 10:203-209, 1982
7. Brooks WH, Latta RB, Mahaley MS, Roszman TL, Dudka L, Skaggs C: Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status. J Neurosurg 54:331-337, 1981
8. Burger PC, Heinz ER, Shibata T, Kleihues P: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68:698-704, 1988
9. Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Gaetani P, et al: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49:1505-1508, 1989
10. de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H, et al: Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. Embo J 6:3673-3677, 1987
11. Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, et al: Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 109:893-899, 2004
12. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238, 2001
13. Dix AR, Brooks WH, Roszman TL, Morford LA: Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100:216-232, 1999
14. Elliott L, Brooks W, Roszman T: Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 78:919-922, 1987
15. Elliott LH, Brooks WH, Roszman TL: Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132:1208-1215, 1984
16. Elliott LH, Brooks WH, Roszman TL: Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Clin Invest 86:80-86, 1990
17. Fong L, Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245-273, 2000
18. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261-3282, 1994
19. Hintzen RQ, Voormolen J, Sonneveld P, van Duinen SG: Glioblastoma causing granulocytosis by secretion of granulocyte-colony-stimulating factor. Neurology 54:259-261, 2000
20. Kikuchi T, Abe T, Ohno T: Effects of glioma cells on maturation of dendritic cells. J Neurooncol 58:125-130, 2002
21. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337-344, 2001
22. Lebecque S: Antigen receptors and dendritic cells. Vaccine 18:1603-1605, 2000
23. Lipscomb MF, Masten BJ: Dendritic cells: immune regulators in health and disease. Physiol Rev 82:97-130, 2002
24. Matasic R, Dietz AB, Vuk-Pavlovic S: Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol 66:909-914, 1999
25. McIlroy D, Gregoire M: Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52:583-591, 2003
26. McVicar DW, Davis DF, Merchant RE: In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect. J Neurosurg 76:251-260, 1992
27. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, et al: Inhibition of the differentiation of dendritic cells from CD34(1) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778-4791, 1998
28. Morford LA, Dix AR, Brooks WH, Roszman TL: Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors. J Neurosurg 91:935-946, 1999
29. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415-4425, 1997
30. Nitta T, Hishii M, Sato K, Okumura K: Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649:122-128, 1994
31. Parney IF, Hao C, Petruk KC: Glioma immunology and immunotherapy. Neurosurgery 46:778-772, 2000
32. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, et al: Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 162:6473-6481, 1999
33. Prins RM, Graf MR, Merchant RE, Black KL, Wheeler CJ: Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression. J Neurooncol 64:45-54, 2003
34. Roth W, Weller M: Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 56:481-506, 1999
35. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kuhl J, Demaerel P, et al: Surgery and adjuvant dendritic cell-based tumor vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91:1656-1662, 2004
36. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147, 2003
37. Sorg RV, Andres S, Kogler G, Fischer J, Wernet P: Phenotypic and functional comparison of monocytes from cord blood and granulocyte colony-stimulating factor-mobilized apheresis products. Exp Hematol 29:1289-1294, 2001
38. Sorg RV, Özcan Z, Brefort T, Fischer J, Ackermann R, Müller M, et al: Clinical-scale generation of dendritic cells in a closed system. J Immunotherapy 26:374-383, 2003
39. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH: Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159:4772-4780, 1997
40. Strobl H, Knapp W: TGF-beta1 regulation of dendritic cells. Microbes Infect 1:1283-1290, 1999
41. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40:151-160, 1998
42. Van Meir E, Sawamura Y, Diserens AC, Hamou MF, de Tribolet N: Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 50:6683-6688, 1990
43. Woiciechowsky C, Asadullah K, Nestler D, Schoning B, Glockner F, Docke WD, et al: Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol 84:164-171, 1998
44. Wood GW, Morantz RA: Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells. J Neurooncol 1:87-94, 1983
45. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al: Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:1172-1179, 2003
46. Yamanaka R, Yajima N, Abe T, Tsuchiya N, Homma J, Narita M, et al: Dendritic cell-based glioma immunotherapy (review). Int J Oncol 23:5-15, 2003
47. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, et al: Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111:727-735, 2003
48. Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, et al: Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 62:2583-2591, 2002
49. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979, 2004
50. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001
51. Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, et al: Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162:4882-4892, 1999